Binds Hormone, Lymphokine, Cytokine, Or Other Secreted Growth Regulatory Factor, Differentiation Factor, Intercellular Mediator, Or Neurotransmitter (e.g., Insulin, Human Chorionic Gonadotropin, Glucagon, Cardiodilatin, Interleukin, Interferon, Norepinephrine, Epinephrine, Acetylcholine, Etc.) Patents (Class 530/389.2)
-
Publication number: 20140004128Abstract: The present invention provides human, humanized and/or chimeric antibodies as well as fragments, derivatives/conjugates and compositions thereof with a specific binding affinity for interleukin-18. The invention includes the use of these antibodies for diagnosing and treating diseases associated with increased IL-18 activity, the latter in the form of a pharmaceutical composition.Type: ApplicationFiled: December 20, 2011Publication date: January 2, 2014Applicant: Medimmune LimitedInventors: Claire Dobson, Steven Lane, Philip Newton, Martin Schwickart, Ann-Charlott Steffen
-
Publication number: 20130344086Abstract: The invention provides antibodies that are modified to reduce aggregration propensity, and methods of producing such antibodies. The present invention also provides particularly stable and soluble scFv antibodies and Fab fragments specific for TNF, which comprise specific light chain and heavy chain sequences that are optimized for stability, solubility, in vitro and in vivo binding of TNF, and low immunogenicity. The nucleic acids, vectors and host cells for expression of the recombinant antibodies of the invention, methods for isolating them and the use of said antibodies in medicine are also disclosed.Type: ApplicationFiled: August 28, 2013Publication date: December 26, 2013Applicant: ESBATech, An Alcon Biomedical Research Unit LLCInventors: Leonardo Jose Borras, David Urech
-
Publication number: 20130338344Abstract: The instant invention relates to the field of protein production and purification, and in particular to compositions and processes for controlling the amount of charge variants, aggregates, and fragments of a protein of interest, as well as host cell proteins, present in purified preparations by applying particular chromatography conditions during such protein purification.Type: ApplicationFiled: March 14, 2013Publication date: December 19, 2013Applicant: ABBVIE INC.Inventors: Natarajan Ramasubramanyan, Lihua Yang, Matthew Omon Herigstad, Hong Yang
-
Publication number: 20130336975Abstract: The present invention is directed to antibodies and fragments thereof having binding specificity for NGF. Another embodiment of this invention relates to the antibodies described herein, and binding fragments thereof, comprising the sequences of the VH, VL and CDR polypeptides described herein, and the polynucleotides encoding them. The invention also contemplates conjugates of anti-NGF antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. The invention also contemplates methods of making said anti-NGF antibodies and binding fragments thereof. Embodiments of the invention also pertain to the use of anti-NGF antibodies, and binding fragments thereof, for the diagnosis, assessment and treatment of diseases and disorders associated with NGF.Type: ApplicationFiled: March 15, 2013Publication date: December 19, 2013Inventors: Benjamin H. Dutzar, Brian R. Kovacevich, Patricia Dianne McNeill, Danielle M. Mitchell, Ethan W. Ojala, Pei Fan, Jens Billgren, Erica A. Stewart, Corinne C. Akatsuka, Betty Yu-Ching Chang, John A. Latham, Leon F. Garcia-Martinez
-
Publication number: 20130337018Abstract: In accordance with the invention, the development and use of antibodies within the digestive tract is provided. Antibodies are described that are used to treat disorders associated with altered permeability of the digestive tract. Antibodies are described with increased stability within the environment of the digestive tract. Antibodies are described with enhanced permeability to a compromised digestive tract.Type: ApplicationFiled: June 7, 2013Publication date: December 19, 2013Applicant: Avaxia Biologics, IncorporatedInventor: Barbara S. Fox
-
Publication number: 20130330357Abstract: Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor ? (hTNF?) are disclosed. These antibodies have high affinity for hTNF? (e.g., Kd=10?8 M or less), a slow off rate for hTNF? dissociation (e.g., Koff=10?3 sec?1 or less) and neutralize hTNF? activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hTNF? and for inhibiting hTNF? activity, e.g., in a human subject suffering from a disorder in which hTNF? activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.Type: ApplicationFiled: August 12, 2013Publication date: December 12, 2013Applicant: ABBVIE BIOTECHNOLOGY LTDInventors: Jochen G. Salfeld, Deborah J. Allen, Zehra Kaymakcalan, Boris Labkovsky, John A. Mankovich, Brian T. McGuinness, Andrew J. Roberts, Paul Sakorafas, Hendricus R.J.M. Hoogenboom, David Schoenhaut, Tristan J. Vaughan, Michael White, Alison J. Wilton
-
Publication number: 20130330355Abstract: The present invention provides anti-IL-1? monoclonal antibodies and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of inflammatory and other diseases.Type: ApplicationFiled: September 9, 2011Publication date: December 12, 2013Applicant: APEXIGEN, INC.Inventors: Yaohuang Ke, Sum Wai Pierre Lee, Yongke Zhang
-
Publication number: 20130330719Abstract: The present disclosure relates to methods for the diagnosis and evaluation of neoplastic disorders, particularly non-small cell lung cancer. Assays are described in which patient test samples are analyzed for the presence of one or more specific EML4-ALK fusion genes associated with neoplastic disorders.Type: ApplicationFiled: December 16, 2010Publication date: December 12, 2013Inventors: Heather R. Sanders, Maher Albitar, Aurelia Meloni-Ehrig
-
Publication number: 20130330333Abstract: This invention concerns pathological angiogenesis and cancer, related treatment methods, and related compositions. Also disclosed are related diagnosis kits and methods.Type: ApplicationFiled: February 10, 2012Publication date: December 12, 2013Applicant: The Rockefeller UniversityInventors: Sohail Tavazoie, Nils Halberg, Kim Png
-
Publication number: 20130330356Abstract: Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor ? (hTNF?) are disclosed. These antibodies have high affinity for hTNF? (e.g., Kd=10?8 M or less), a slow off rate for hTNF? dissociation (e.g., Koff=10?3 sec?1 or less) and neutralize hTNF? activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hTNF? and for inhibiting hTNF? activity, e.g., in a human subject suffering from a disorder in which hTNF? activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.Type: ApplicationFiled: August 12, 2013Publication date: December 12, 2013Applicant: ABBVIE BIOTECHNOLOGY LTD.Inventors: Jochen G. Salfeld, Deborah J. Allen, Zehra Kaymakcalan, Boris Labkovsky, John A. Mankovich, Brian T. McGuinness, Andrew J. Roberts, Paul Sakorafas, Hendricus R.J.M. Hoogenboom, David Schoenhaut, Tristan J. Vaughan, Michael White, Alison J. Wilton
-
Patent number: 8603972Abstract: The invention relates to protracted GLP-1 compounds and therapeutic uses thereof.Type: GrantFiled: March 20, 2006Date of Patent: December 10, 2013Assignee: Novo Nordisk A/SInventors: Jesper Lau, Florencio Zaragoza Dorwald, Lauge Schaffer, Thomas Kruse Hansen
-
Publication number: 20130323237Abstract: The present invention relates to human thymic stromal lymphopoietin (hTSLP) antibodies and especially those which neutralize hTSLP activity. It further relates to methods for using anti-hTSLP antibody molecules in diagnosis or treatment of hTSLP related disorders, such as asthma, atopic dermatitis, allergic rhinitis, fibrosis, inflammatory bowel disease and Hodgkin's lymphoma.Type: ApplicationFiled: March 15, 2013Publication date: December 5, 2013Inventors: Michael BARDROFF, Matthew EDWARDS, Mehmet TUR, Olaf RATSCH
-
Publication number: 20130324704Abstract: The present invention concerns antibodies to EGFL7 and the uses of same.Type: ApplicationFiled: July 17, 2013Publication date: December 5, 2013Inventors: Weilan YE, Mark S. Dennis, Jill Fredrickson
-
Publication number: 20130323248Abstract: There is disclosed compositions and methods relating to or derived from anti-DLL-4 antibodies. More specifically, there is disclosed fully human antibodies that bind DLL-4, DLL-4-binding fragments and derivatives of such antibodies, and DLL-4-binding polypeptides comprising such fragments. Further still, there is disclosed nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having DLL-4 related disorders or conditions, including various inflammatory disorders and various cancers.Type: ApplicationFiled: May 28, 2013Publication date: December 5, 2013Applicant: Sorrento Therapeutics Inc.Inventors: Edwige Gros, Yanliang Zhang, Heyue Zhou, Randy Gastwirt
-
Patent number: 8597646Abstract: The instant invention provides methods and compositions for the treatment and prevention of Marfan syndrome and related diseases, disorders and conditions. The invention further provides pharmaceutical compositions and kits for the treatment and prevention of Marfan syndrome and related diseases, disorders and conditions.Type: GrantFiled: October 25, 2006Date of Patent: December 3, 2013Assignee: The Johns Hopkins UniversityInventors: Harry C. Dietz, Daniel P. Judge, Enid R. Neptune, Ronald Cohn, Jennifer Habashi
-
Publication number: 20130315928Abstract: The invention relates to a ligand of a luteinizing hormone (LH), characterized in that it comprises the paratope of an ovine anti-LH antibody of which the variable domain of the heavy chain contains the following CDRs: —VH-CDR1, defined by the sequence GYTFTNYW (SEQ ID NO: 13); —VH-CDR2, defined by the sequence IYPGGGYT (SEQ ID NO: 14); —VH-CDR3, defined by the sequence ARTPLYGSSYGGFAY (SEQ ID NO: 15); and the variable domain of the light chain contains the following CDRs: —VL-CDR1, defined by the sequence QGISNY (SEQ ID NO: 16); —VL-CDR2, defined by the sequence YTS; —VL-CDR3, defined by the sequence QQYSKLPWT (SEQ ID NO: 17). The invention also relates to a ligand-gonadotrophin (LH, hCG, FSH) complex. The ligand or the complex according to the invention can be used to induce ovulation in a female mammal.Type: ApplicationFiled: November 21, 2011Publication date: November 28, 2013Inventors: Marie-Christine Maurel, Eric Reiter, Florian Guillou, Nicolas Aubrey
-
Publication number: 20130316934Abstract: Detection of particles in a liquid beneficial agent contained within a container includes selectively illuminating at least a portion of the liquid beneficial, obtaining an image from the illuminated portion of the liquid beneficial agent, analyzing image data representing the image, using a data processor, to obtain a particle concentration, measuring an image intensity value of the image data using the data processor, and determining a quality level of the liquid beneficial agent using the data processor based on the particle concentration and the measured image intensity value.Type: ApplicationFiled: March 15, 2013Publication date: November 28, 2013Inventors: Edmund Matayoshi, Jie Wang
-
Patent number: 8591901Abstract: The present invention relates to antibody molecules, in particular antibody molecules that bind Transforming Growth Factor beta (TGF?), and uses thereof. More particularly, the invention relates to antibody molecules that bind and preferably neutralize TGF?1, TGF?2 and TGF?3, so-called “pan-specific” antibody molecules, and uses of such antibody molecules. Preferred embodiments within the present invention are antibody molecules, whether whole antibody (e.g. IgG, such as IgG1 or IgG4) or antibody fragments (e.g. scFv, Fab, dAb).Type: GrantFiled: September 13, 2012Date of Patent: November 26, 2013Assignees: Genzyme Corporation, Optein, IncInventors: Steven R Ledbetter, Celia P Hart, Robert G Holgate, Lutz U Jermutus, Catriona L Buchanan, Alexander R Duncan, Donna K Finch
-
Publication number: 20130310281Abstract: The present invention provides novel antigen-binding proteins derived from human germline VH domains, having improved expression and improved biophysical characteristics.Type: ApplicationFiled: January 27, 2012Publication date: November 21, 2013Applicant: Glaxo Group LimitedInventors: Emma R. Harding, Ekaterini Kotsopoulou, Alan Peter Lewis, Susannah Thornhill, Mark Uden
-
Publication number: 20130309236Abstract: The present invention relates generally to the generation and characterization of neutralizing anti-IFN-? monoclonal antibodies with broad reactivity against various IFN-? subtypes. The invention further relates to the use of such anti-IFN-? antibodies in the diagnosis and treatment of disorders associated with increased expression of TUN-?, in particular, autoimmune disorders such as insulin-dependent diabetes mellitus (IDDM) and systemic lupus erythematosus (SLE).Type: ApplicationFiled: July 31, 2013Publication date: November 21, 2013Applicant: Genentech, Inc.Inventors: Anan CHUNTHARAPAI, Jin K. Kim, Leonard G. Presta, Timothy Stewart
-
Publication number: 20130302835Abstract: Monoclonal antibodies which bind specifically to the proinflammatory cytokine pyroglutamate MCP-1 (MCP-1 N1pE).Type: ApplicationFiled: July 23, 2013Publication date: November 14, 2013Inventors: Holger Cynis, Hans-Ulrich Demuth, Jens-Ulrich Rahfeld, Stephan Schilling, Kathrin Gans, Sonja Kampfer
-
Publication number: 20130302347Abstract: Described herein is a novel receptor-ligand interaction and agents that may modify and/or block the interaction. Methods, uses, reagents and kits for the modulation of ligand activities related to its interaction with the novel receptor are disclosed. Also disclosed are therapeutic uses of reagents in treating inflammation-related disorders.Type: ApplicationFiled: May 23, 2013Publication date: November 14, 2013Inventors: Adrian Lobito, Wenjun Ouyang, Lino C. Gonzalez, JR.
-
Patent number: 8580260Abstract: The present invention relates to human anti-IL-13 binding molecules, particularly antibodies, and to methods for using anti-IL-13 antibody molecules in diagnosis or treatment of IL-13 related disorders, such as asthma, atopic dermatitis, allergic rhinitis, fibrosis, inflammatory bowel disease and Hodgkin's lymphoma.Type: GrantFiled: December 22, 2010Date of Patent: November 12, 2013Assignee: Novartis AGInventors: Emma Michelle Campbell, Sofia Parveen, Joe Buechler, Gunars Valkirs
-
Publication number: 20130295113Abstract: The present disclosure provides compositions and methods relating to antibodies that specifically bind to human erythropoietin. The disclosure provides nucleic acids encoding such antibodies and methods of making and using such antibodies.Type: ApplicationFiled: May 7, 2013Publication date: November 7, 2013Inventors: Daniel T. Mytych, Narendra Chirmule, Dohan K. Weeraratne
-
Publication number: 20130295112Abstract: The present invention provides anti-nerve growth factor (NGF) antibodies that contain an IgG4 constant region comprising a stabilizing hinge region mutation and wherein the antibodies exhibit an unexpectedly long serum half life in cynomolgus monkeys. Pharmaceutical compositions comprising the anti-NGF antibodies, nucleic acids encoding the NGF antibodies, host cells for expressing the NGF antibodies and methods of using the antibodies for treating NGF-related diseases or conditions are also provided.Type: ApplicationFiled: May 2, 2013Publication date: November 7, 2013Applicant: Abbott Research B.V.Inventor: Abbott Research B.V.
-
Publication number: 20130296184Abstract: The present invention relates to a method for diagnosing Lyme disease in a subject, the method comprising the steps of: (a) obtaining a sample from said subject, (b) contacting said sample with a source of Borrelia antigens and (c) determining the expression level of a pro-inflammatory cytokine in said sample at the end of step (b).Type: ApplicationFiled: September 21, 2011Publication date: November 7, 2013Applicant: STICHTING KATHOLIEKE UNIVERSITEITInventors: Leonardus Antonius Bernardus Joosten, Mihai Gheorghe Netea, Johannes Willem Maarten van der Meer, Bart Julian Kullberg
-
Publication number: 20130287762Abstract: The disclosure provides novel antibodies against growth and differentiation factor-8 (GDF-8), in particular human antibodies, and antibody fragments, including those that inhibit GDF-8 activity in vitro and/or in vivo. The disclosure also provides methods for diagnosing, preventing, or treating degenerative disorders of muscle or bone, or disorders of insulin metabolism.Type: ApplicationFiled: November 30, 2012Publication date: October 31, 2013Applicants: MEDIMMUNE LIMITED, WYETHInventors: Geetruida M. Veldman, Monique V. Davies, Kening Song, Neil M. Wolfman, Kristie Grove, Anne Field, Caroline Russell, Viia Valge-Archer
-
Publication number: 20130287684Abstract: The present invention relates to novel therapeutic recombinant antibodies directed against HER3 (ErbB3), as well as compositions comprising mixtures of at least two of said recombinant anti-HER3 antibodies, and use of the antibodies and antibody compositions for treatment of cancer.Type: ApplicationFiled: October 31, 2011Publication date: October 31, 2013Applicant: SYMPHOGEN A/SInventors: Mikkel Wandahl Pedersen, Helle Jacobsen, Klaus Koefoed
-
Publication number: 20130287791Abstract: Provided are methods and compositions for treatment of cancer. In particular, these methods and compositions may include an inhibitor of a deubiquitinating enzyme. In certain aspects, these methods and compositions may include a modulator of glucose metabolism. Also provided are methods of assaying the glucose content of cells and tissues using detection of uH2B.Type: ApplicationFiled: March 13, 2013Publication date: October 31, 2013Inventor: C. Wilson Xu
-
Patent number: 8569462Abstract: The present disclosure relates, in general, to materials and methods for antibodies specific for transforming growth factor beta (TGF?), including TGF?1, TGF?2 and TGF?3, and uses of these antibodies in the treatment of subjects having cancer, an eye disease, condition or disorder, fibrosis, including ophthalmic fibrosis or fibrosis of the eye, and other conditions or disorders related to TGF? expression.Type: GrantFiled: June 1, 2012Date of Patent: October 29, 2013Assignee: Xoma Technology Ltd.Inventors: Daniel Bedinger, Shireen S. Khan, Amer Mirza, Ajay J. Narasimha, Toshihiko Takeuchi
-
Publication number: 20130273071Abstract: The present invention provides novel antibodies that immunospecifically bind to an IL-9 polypeptide and compositions comprising said antibodies. The present invention also provides methods and compositions preventing, treating, managing, and/or ameliorating diseases and disorders associated with aberrant expression and/or activity of IL 9 or IL-9 receptor or subunits thereof, autoimmune diseases, inflammatory diseases, proliferative diseases, and infections comprising administration of one or more antibodies thereof that immunospecifically bind to an IL-9 polypeptide. The invention also encompasses methods and compositions for diagnosing, monitoring, and prognosing these disorders. The present invention further relates to articles of manufacture and kits comprising antibodies that immunospecifically bind to an IL-9 polypeptide.Type: ApplicationFiled: June 6, 2013Publication date: October 17, 2013Inventors: Jennifer Lynne Reed, Herren Wu, Ying Tang, Julian Davies, Jeffry Watkins
-
Publication number: 20130273064Abstract: The present invention relates to a binding compound which binds to human APRIL. More specifically the invention provides, compositions of anti-APRIL specific antibodies and methods to use such antibodies in modulating the biological activity APRIL, particularly in inflammatory diseases, inhibition of cell proliferation and cancer.Type: ApplicationFiled: March 11, 2013Publication date: October 17, 2013Applicant: BIONOVION HOLDING B.V.Inventors: Jan Paul Medema, Hans Van Eenennaam, Marco Guadagnoli, Fiona Clare Kimberley, Uyen Truong Phan
-
Publication number: 20130273068Abstract: The invention provides antibodies which bind to the ADP-ribosyl cyclase 2. Nucleic acid molecules encoding the antibodies, expression vectors, host cells and methods for expressing the antibodies are also provided. The antibodies may be used for the treatment of human cancers, including acute myeloid leukemia (AML), B-cell chronic lymphocytic leukemia, breast cancer, colorectal cancer, kidney cancer, head and neck cancer, lung cancer, ovarian cancer and pancreatic cancer and human inflammatory diseases, including asthma, gout, crohns, lupus, multiple sclerosis, rheumatoid arthritis, psoriasis, diabetes and atherosclerotic.Type: ApplicationFiled: March 15, 2013Publication date: October 17, 2013Inventors: Christian ROHLFF, Jonathan Alexander TERRETT
-
Publication number: 20130266579Abstract: Provided herein are modified anti-EGFR antibodies and nucleic acid molecules encoding modified anti-EGFR antibodies. Also provided are methods of treatment and uses using modified anti-EGFR antibodies.Type: ApplicationFiled: March 8, 2013Publication date: October 10, 2013Inventors: Ge Wei, Gregory I. Frost, Lei Huang, H. Michael Shepard, Daniel Edward Vaughn
-
Publication number: 20130266571Abstract: Disclosed is a crystalline human CR2 protein in complex with C3d, and the three dimensional structure of the crystalline complex. Also disclosed are methods of use of the structure, particularly for structure-based identification of compounds that bind to CR2 and inhibit or enhance the binding of CR2 to a natural ligand, that bind to CR2 and agonize or antagonize the receptor, that bind to CR2 and inhibit or enhance CR2 dimerization, or that use the C3-binding ability of CR2 as a drug delivery vehicle. Also disclosed are therapeutic compounds obtained by such methods and uses for such compounds.Type: ApplicationFiled: June 13, 2013Publication date: October 10, 2013Inventors: Xiaojiang CHEN, V. Michael Holers
-
Publication number: 20130266581Abstract: Anti-VEGF antibodies and variants thereof, including those having high affinity for binding to VEGF, are disclosed. Also provided are methods of using phage display technology with naïve libraries to generate and select the anti-VEGF antibodies with desired binding and other biological activities. Further contemplated are uses of the antibodies in research, diagnostic and therapeutic applications.Type: ApplicationFiled: June 25, 2013Publication date: October 10, 2013Inventors: Germaine FUH, Hans-Peter Gerber, Wei-Ching Liang, Frederic Fellouse, Sachdev S. Sidhu, Christian Wiesmann
-
Publication number: 20130259799Abstract: Antigen binding proteins that bind to human GM-CSF protein are provided. Nucleic acids encoding the antigen binding protein, vectors, and cells encoding the same are also provided. The antigen binding proteins can inhibit binding of GM-CSF to GM-CSFR, inhibit GM-CSF-induced proliferation and signaling of myeloid lineage cell lines and inhibit GM-CSF-induced activation of human monocytes.Type: ApplicationFiled: June 11, 2013Publication date: October 3, 2013Inventors: Jacqueline A. Kirchner, Kenneth A. Brasel, Kara Olson, Jose Carlos Escobar, Dauphine Barone
-
Publication number: 20130259868Abstract: Complexes containing one or more modular recognition domains (MRDs) and MRDs attached to scaffold's including antibodies are described. The manufacture of these complexes are the use of these complexes to treat and diagnose diseases and disorders are also described.Type: ApplicationFiled: March 15, 2013Publication date: October 3, 2013Inventors: Viktor ROSCHKE, David Lafleur, David M. Hilbert, Peter Kiener
-
Patent number: 8545849Abstract: The invention provides antibodies that are modified to reduce aggregration propensity, and methods of producing such antibodies. The present invention also provides particularly stable and soluble scFv antibodies and Fab fragments specific for TNF, which comprise specific light chain and heavy chain sequences that are optimized for stability, solubility, in vitro and in vivo binding of TNF, and low immunogenicity. The nucleic acids, vectors and host cells for expression of the recombinant antibodies of the invention, methods for isolating them and the use of said antibodies in medicine are also disclosed.Type: GrantFiled: October 21, 2011Date of Patent: October 1, 2013Assignee: ESBATech, an Aclon Biomedical Research Unit LLCInventors: Leonardo Jose Borras, David Urech
-
Patent number: 8540988Abstract: This invention relates, in part, to unique and newly identified genetic polynucleotides involved in the process of bone remodeling, variants and derivatives of the polynucleotides and corresponding polypeptides, uses of the polynucleotides, polypeptides, variants and derivatives, and methods and compositions for the amelioration of symptoms caused by bone remodeling disorders. Disclosed in particular are the isolation and identification of polynucleotides, polypeptides variants and derivatives involved in osteoclast activity, validation of the identified polynucleotides for their potential as therapeutic targets and use of the polynucleotides, polypeptides, variants and derivatives for the amelioration of disease states and research purposes.Type: GrantFiled: June 2, 2011Date of Patent: September 24, 2013Assignee: Alethia Biotherapeutics Inc.Inventors: Roy Rabindranauth Sooknanan, Gilles Bernard Tremblay, Mario Filion
-
Publication number: 20130243760Abstract: The present invention provides and includes monoclonal antibodies (mAbs) preferentially selective for HER2 antigens, hybridoma lines that secrete these HER2 antibodies or antibody fragments, and the use of such antibodies and antibody fragments to detect HER2 antigens, particularly those expressed by cancer cells. The present invention also includes antibodies that are specific for or show preferential binding to a soluble or secreted form of HER2. The present invention also includes an antibody or antibody fragment that is capable of reducing the activity of HER2 in at least one form, including a soluble form or a secreted form. The present invention further includes chimeric antibodies, processes for producing monoclonal and chimeric antibodies or monoclonal or chimeric antibodies, and their therapeutic uses, particularly in the detection of cancer most preferentially in human breast, stomach, and colon.Type: ApplicationFiled: May 1, 2013Publication date: September 19, 2013Applicant: Alper BioTech, LLCInventor: Özge Alper
-
Publication number: 20130243789Abstract: Disclosed are useful constructs and methods for the expression of proteins using primary translation products that are processed within a recombinant host cell. Constructs comprising a single open reading frame (sORF) are described for protein expression including expression of multiple polypeptides. A primary translation product (a pro-protein or a polyprotein) contains polypeptides such as inteins or hedgehog family auto-processing domains, or variants thereof, inserted in frame between multiple protein subunits of interest. Also disclosed are independent aspects of conducting efficient expression, secretion, and/or multimeric assembly of proteins such as immunoglobulins.Type: ApplicationFiled: January 11, 2013Publication date: September 19, 2013Applicant: Abbott LaboratoriesInventors: Gerald R. Carson, Jochen G. Salfeld, Dean A. Regier, Jijie Gu, Wendy Gion, Yune Z. Kunes
-
Patent number: 8536311Abstract: The present invention relates to an inhibitor protein of the wnt signal path, a DNA encoding such a protein and a process for the preparation of such a protein. In addition, this invention concerns the use of the DNA and the protein as well as antibodies directed against the protein.Type: GrantFiled: November 20, 2006Date of Patent: September 17, 2013Assignee: Deutsches Krebsforschungszentrum Stiftung des Offentlichen RechtsInventors: Christof Niehrs, Andrei Glinka
-
Publication number: 20130236471Abstract: The present invention relates to anti-IL-36R binding compounds, in particular new anti-IL-36R antibodies and therapeutic and diagnostic methods and compositions for using the same.Type: ApplicationFiled: November 14, 2012Publication date: September 12, 2013Applicant: Boehringer Ingelheim GmbHInventors: Su-Ellen BROWN, Keith Canada, Lukasz Chlewicki, Michael Howell, Detlev Mennerich, Joseph Robert Woska, JR.
-
Publication number: 20130236473Abstract: A major object of the present invention is to provide a novel therapeutic or prophylactic agent for at least one disease or symptom selected from the group consisting of autoimmune diseases, inflammatory diseases, allergic diseases, and symptoms accompanying organ transplants; the therapeutic or prophylactic agent artificially controls the activity of IL-6 amplifier, thus controlling immune reactions in living organisms. Another object of the present invention is to provide an immunosuppressant, an inflammatory cytokine production inhibitor, and an IL-6 amplifier inhibitor. The compound that inhibits expression of the function of a protein belonging to ErbB1 pathway provided as means for achieving the object is capable of suppressing the activity of IL-6 amplifier, thereby reducing production of inflammatory cytokine such as IL-6.Type: ApplicationFiled: September 14, 2011Publication date: September 12, 2013Applicant: OSAKA UNIVERSITYInventors: Toshio Hirano, Masaaki Murakami
-
Publication number: 20130230510Abstract: A method for inhibition of leukemic stem cells expressing IL-3R.alpha.; (CD 123), comprises contacting the cells with an antigen binding molecule comprising a Fc region or a modified Fc region having enhanced Fc effector function, wherein the antigen binding molecule binds selectively to IL-3R.alpha. (CD123). The invention includes the treatment of a hematologic cancer condition in a patient by administration to the patient of an effective amount of the antigen binding molecule.Type: ApplicationFiled: December 4, 2012Publication date: September 5, 2013Applicants: University Health Network, CSL LimitedInventors: John Edgar Dick, Liqing Jin, Gino Luigi Vairo, David Paul Gearing, Samantha Jane Busfield
-
Publication number: 20130230886Abstract: Provided herein are antibodies, antigen binding portions, and derivatives thereof that are capable of binding tumor necrosis factor alpha (TNF?); nucleic acids encoding the antibodies, antigen binding portions, and derivatives thereof, including complementary nucleic acids; vectors; and host cells containing the nucleic acids.Type: ApplicationFiled: March 13, 2013Publication date: September 5, 2013Inventors: Christian Votsmeier, Uwe Gritzan, Kornelia Kirchner, Michael Strerath, Kerstin Baral, Ulrich Haupts, Wayne M. Coco, Susanne Steinig, Andreas Scheidig, Klaus Pellengahr, Simone Brückner, Hanna Plittersdorf, Peter Scholz, Jan Tebbe
-
Patent number: 8524866Abstract: An antibody or an antigen binding fragment thereof which binds to mammalian ?7 subunit of a nicotinic acetylcholine receptor or its functional variant and which is an agonist of said receptor or variant. Pharmaceutical compositions comprising same. A method of treating a subject suffering from an inflammatory condition comprising administering to said subject an antibody or an antigen-binding fragment as described herein.Type: GrantFiled: November 15, 2006Date of Patent: September 3, 2013Assignee: The Feinstein Institute for Medical ResearchInventors: Lihong Yang, Kevin J. Tracey
-
Publication number: 20130224219Abstract: The drug for the prophylaxis of HIV infection and for the prophylaxis and treatment of diseases caused by or associated with HIV, including AIDS, comprises an activated, potentiated form of antibodies to a protein or peptide of the immune system which interacts with the HIV or has a content and/or functional activity which changes in connection with an HIV infection.Type: ApplicationFiled: July 15, 2011Publication date: August 29, 2013Inventors: Oleg Iliich Epshtein, Sergei Alexandrovich Tarasov
-
Publication number: 20130209445Abstract: The present invention relates to Fc variants having decreased affinity for Fc?RIIb, methods for their generation, Fc polypeptides comprising optimized Fc variants, and methods for using optimized Fc variants.Type: ApplicationFiled: March 8, 2013Publication date: August 15, 2013Applicant: Xencor, Inc.Inventors: Gregory A. Lazar, Wei Dang, John Desjarais, Sher Bahadur Karki, Omid Vafa, Robert Hayes, Jost Vielmetter